Clinical Trials

29 enrolled

Liver Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07529483 2026-04-14

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts

35 enrolled

Pancreatic Cystic Neoplasm

NCT07524413 2026-04-13

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

514 enrolled

Nasopharyngeal Neoplasms

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Lymphoid

Hodgkin Disease

NCT07332351 2026-03-13

TRIFECTA

33 enrolled

Urinary Bladder Neoplasms

NCT07447076 2026-03-03

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

29 enrolled

Rhabdoid Tumor

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Pancreatic cancer, adult

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07418931 2026-02-18

CECYDE

108 enrolled

Thoracic

Advanced Squamous Non-Small Cell Lung Cancer

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT07369791 2026-01-28

NOBLE

76 enrolled

Advanced Biliary Tract Cancer(BTC)

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Nasopharyngeal Neoplasms

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2/3 Not yet recruiting

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Breast

Breast Neoplasms

NCT07353294 2026-01-20

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Phase 1 Not yet recruiting

12 enrolled

Lymphatic Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

10 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07272109 2025-12-15

PTCA199-16

210 enrolled

Pancreatic Neoplasms

NCT06177522 2025-11-18

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Pancreatic Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

28 enrolled

Urinary Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07184021 2025-09-19

No Acronym

Urinary Bladder Neoplasms

NCT07158489 2025-09-05

ORIGIN2

47 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

10 enrolled

Phase 1 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

12 enrolled

Urinary Bladder Neoplasms, Neoplasms

NCT07108504 2025-08-07

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Neoplasms

NCT07109167 2025-08-07

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Phase 1/2 Not yet recruiting

Biliary Tract Neoplasms

NCT07064863 2025-07-17

BCG-TIME

31 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07003815 2025-06-04

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

62 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06903273 2025-03-30

TisGCS for BTC

35 enrolled

Phase 1/2 Not yet recruiting

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

60 enrolled

Pancreatic Cancer Resectable

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

210 enrolled

Phase 4 Not yet recruiting

Urinary Bladder Neoplasms

NCT06818773 2025-02-10

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

35 enrolled

Biliary Tract Neoplasms

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT06274879 2025-01-09

Ablatio

36 enrolled

Bile Duct Neoplasms

NCT06713057 2024-12-03

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06623162 2024-10-04

SASAN-SPARING

70 enrolled

Mibc

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

104 enrolled

Pancreatic Neoplasms

NCT06611826 2024-09-25

GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC

41 enrolled

Nasopharyngeal Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT06569225 2024-08-26

NEOLANGIO

40 enrolled

Biliary Tract Neoplasms

NCT06567600 2024-08-22

Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

43 enrolled

Phase 1/2 Not yet recruiting

Cholangiocarcinoma

NCT06513455 2024-07-22

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

132 enrolled

Pancreatic Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

63 enrolled